Logo image of ALSMA.PA

SMAIO SA (ALSMA.PA) Stock Fundamental Analysis

EPA:ALSMA - Euronext Paris - Matif - FR0014005I80 - Common Stock - Currency: EUR

4.96  +0.64 (+14.81%)

Fundamental Rating

3

Overall ALSMA gets a fundamental rating of 3 out of 10. We evaluated ALSMA against 59 industry peers in the Health Care Equipment & Supplies industry. While ALSMA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ALSMA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALSMA has reported negative net income.
ALSMA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ALSMA reported negative net income in multiple years.
ALSMA had negative operating cash flow in 4 of the past 5 years.
ALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M

1.2 Ratios

ALSMA has a worse Return On Assets (-14.21%) than 66.10% of its industry peers.
ALSMA's Return On Equity of -22.35% is on the low side compared to the rest of the industry. ALSMA is outperformed by 64.41% of its industry peers.
Industry RankSector Rank
ROA -14.21%
ROE -22.35%
ROIC N/A
ROA(3y)-2.24%
ROA(5y)-17.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSMA.PA Yearly ROA, ROE, ROICALSMA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 400

1.3 Margins

The Gross Margin of ALSMA (88.45%) is better than 93.22% of its industry peers.
ALSMA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALSMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.68%
ALSMA.PA Yearly Profit, Operating, Gross MarginsALSMA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

ALSMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALSMA remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ALSMA has less shares outstanding
Compared to 1 year ago, ALSMA has a worse debt to assets ratio.
ALSMA.PA Yearly Shares OutstandingALSMA.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
ALSMA.PA Yearly Total Debt VS Total AssetsALSMA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

An Altman-Z score of 3.59 indicates that ALSMA is not in any danger for bankruptcy at the moment.
ALSMA has a Altman-Z score of 3.59. This is in the better half of the industry: ALSMA outperforms 62.71% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ALSMA is not too dependend on debt financing.
ALSMA has a Debt to Equity ratio (0.31) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 3.59
ROIC/WACCN/A
WACC7.7%
ALSMA.PA Yearly LT Debt VS Equity VS FCFALSMA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

ALSMA has a Current Ratio of 5.08. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
ALSMA's Current ratio of 5.08 is amongst the best of the industry. ALSMA outperforms 94.92% of its industry peers.
ALSMA has a Quick Ratio of 4.25. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 4.25, ALSMA belongs to the best of the industry, outperforming 98.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.08
Quick Ratio 4.25
ALSMA.PA Yearly Current Assets VS Current LiabilitesALSMA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

6

3. Growth

3.1 Past

ALSMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.01%.
ALSMA shows a decrease in Revenue. In the last year, the revenue decreased by -4.09%.
Measured over the past years, ALSMA shows a very strong growth in Revenue. The Revenue has been growing by 114.98% on average per year.
EPS 1Y (TTM)-24.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-209.52%
Revenue 1Y (TTM)-4.09%
Revenue growth 3Y83.56%
Revenue growth 5Y114.98%
Sales Q2Q%-44.7%

3.2 Future

Based on estimates for the next years, ALSMA will show a very strong growth in Earnings Per Share. The EPS will grow by 43.88% on average per year.
Based on estimates for the next years, ALSMA will show a very strong growth in Revenue. The Revenue will grow by 32.39% on average per year.
EPS Next Y-70.21%
EPS Next 2Y23.77%
EPS Next 3Y43.88%
EPS Next 5YN/A
Revenue Next Year2.79%
Revenue Next 2Y38.75%
Revenue Next 3Y39.74%
Revenue Next 5Y32.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALSMA.PA Yearly Revenue VS EstimatesALSMA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
ALSMA.PA Yearly EPS VS EstimatesALSMA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALSMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSMA.PA Price Earnings VS Forward Price EarningsALSMA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSMA.PA Per share dataALSMA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ALSMA's earnings are expected to grow with 43.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.77%
EPS Next 3Y43.88%

More info and screens

0

5. Dividend

5.1 Amount

ALSMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SMAIO SA

EPA:ALSMA (6/19/2025, 7:00:00 PM)

4.96

+0.64 (+14.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap28.02M
Analysts84.44
Price Target6.12 (23.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.45%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.71
P/FCF N/A
P/OCF N/A
P/B 3.49
P/tB 4.76
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.87
BVpS1.42
TBVpS1.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.21%
ROE -22.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.45%
FCFM N/A
ROA(3y)-2.24%
ROA(5y)-17.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.68%
F-Score1
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.63%
Cap/Sales 25.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.08
Quick Ratio 4.25
Altman-Z 3.59
F-Score1
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)92.26%
Cap/Depr(5y)157.16%
Cap/Sales(3y)36.32%
Cap/Sales(5y)86.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-209.52%
EPS Next Y-70.21%
EPS Next 2Y23.77%
EPS Next 3Y43.88%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.09%
Revenue growth 3Y83.56%
Revenue growth 5Y114.98%
Sales Q2Q%-44.7%
Revenue Next Year2.79%
Revenue Next 2Y38.75%
Revenue Next 3Y39.74%
Revenue Next 5Y32.39%
EBIT growth 1Y-100.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.13%
EBIT Next 3Y47.76%
EBIT Next 5YN/A
FCF growth 1Y-170.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-137.93%
OCF growth 3YN/A
OCF growth 5YN/A